Asia Pacific Metabolomics Market

APAC Metabolomics Market Size (2022 to 2027)

The Asia Pacific Metabolomics Market Size is valued at USD 471.68 Million in 2022 and estimated to grow at a CAGR of 17.92%, to reach USD 1075.44 Million by 2027 during the forecast period 2022 - 2027.

Metabolomics is the rational study of concoction forms comprising metabolites. In particular, metabolomics is the "deliberate investigation of the one of a kind synthetic fingerprints that particular cell forms desert", the study of their little molecules metabolite profiles. The metabolome signifies to the accumulation of all metabolites in natural fleshy tissue, cell, organ or life form, which are the final consequences of cell processes. The Asia Pacific Metabolomics market is developing at a very quick speed.

The increasing biotech ground-breaking work and pharmaceutical consumption are prompting persistent headways in innovation, spelling development for the worldwide metabolomics market. The developing acceptance of metabolomics in customized medicines is one of the key variables boosting the growth of the market. Then again, there are issues with respect to information handling and information examination, which can represent a test for the market. The high cost of instruments and devices can equally be an issue. Further, the necessity for very much skilled specialists and the absence of the same is limiting the improvement of the metabolomics market.

This research report on the Asia-Pacific Metabolomics Market has been segmented and sub-segmented into the following categories:

By Product: 

• GC
• Bioinformatics
• Mass Spectrometry
• HPLC
• UPLC
• NMRS
• Surface-based mass analysis

By Indication: 

• Oncology
• Cardiology
• Inborn Error

By Application: 

• Nutrigenomics
• Toxicology
• Biomarker 
• Drug Discovery

By Country: 

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

On the basis of application, the Biomarker Discovery segment had the largest share in 2016 in the global metabolomics market. Efficiency and reliability have been cited as the reason for the growth of biomarkers. However, collaboration between biotechnology and pharmaceutical companies, the personalized medical segment is expected to have the highest CAGR.

On the basis of region, China and India are likely to increase the market because of the huge population. Also, Asia Pacific is the largest growing segment.

Noteworthy companies leading the Asia Pacific Metabolomics Market analyzed in this report are Agilent Technologies, Inc. (U.S.), Human Metabolome Technologies, Inc. (Japan), Thermo Fisher Scientific, Inc. (U.S.), LECO Corporation (U.S.), Bruker Corporation (U.S.), Shimadzu Corporation (Japan), Metabolon Inc. (U.S.), Danaher Corporation (U.S.), Biocrates Life Sciences AG (Austria), and Waters Corporation (U.S.).